Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Pediatr Infect Dis J. 2013 Nov;32(0 2):i–KK4. doi: 10.1097/01.inf.0000437856.09540.11
Indication First Choice Alternative Comments/Special Issues
Primary Prophylaxis cART to avoid advanced immunodeficiency N/A N/A
Secondary Prophylaxis N/A N/A N/A
Treatment
  • Tinidazole, 50 mg/kg by mouth, administered as 1 dose given with food (maximum 2 g). Note: Based on data from HIV-uninfected children

  • Nitazoxanide. Note: Based on data from HIV-uninfected children
    • 1–3 years: 100 mg by mouth every 12 hours with food for 3 days
    • 4–11 years: 200 mg by mouth every 12 hours with food for 3 days
    • ≥12 years: 500 mg by mouth every 12 hours with food for 3 days
Metronidazole 5 mg/kg by mouth every 8 hours for 5-7 days.

Note: Based on data from HIV-uninfected children
Tinidazole is approved in the United States for children aged ≥3 years. It is available in tablets that can be crushed.

Metronidazole has high frequency of gastrointestinal side effects. A pediatric suspension of metronidazole is not commercially available but can be compounded from tablets. It is not FDA-approved for the treatment of giardiasis.

Supportive Care:
  • Hydration

  • Correction of electrolyte abnormalities

  • Nutritional support

Antimotility agents (e.g., loperamide) should be used with caution in young children.

Key to Abbreviations: cART = combination antiretroviral therapy; FDA = U.S. Food and Drug Administration